|
Trial to Reduce Alloimmunization to Platelets (TRAP) Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Trial to Reduce Alloimmunization to Platelets (TRAP) conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Trial to Reduce Alloimmunization to Platelets (TRAP) Clinical research trials and Trial to Reduce Alloimmunization to Platelets (TRAP) medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Trial to Reduce Alloimmunization to Platelets (TRAP). Trial to Reduce Alloimmunization to Platelets (TRAP) Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Trial to Reduce Alloimmunization to Platelets (TRAP) clinical trial. Participants oftentimes recieve the finest healthcare available for their Trial to Reduce Alloimmunization to Platelets (TRAP) condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Trial to Reduce Alloimmunization to Platelets (TRAP)  Trial to Reduce Alloimmunization to Platelets (TRAP)
Trial to Reduce Alloimmunization to Platelets (TRAP)
For Condition: Blood Platelets,Hematologic Diseases,Immunization,Leukemia, Myelocytic, Acute,Blood Transfusion
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine the best, clinically useful procedure to prevent or minimize platelet alloimmunization as a cause of refractoriness to platelet transfusion in patients undergoing marrow ablative chemotherapy for acute myelogenous leukemia.
Details: BACKGROUND: Between 1971 and 1980, there was a 598 percent increase in the use of platelet concentrates from 0.41 million to more than 2.86 million annually. In contrast, red cell transfusions in the United States rose concurrently from 6.3 million annually to 9.9 million, an increase of 58 percent. Although red cell transfusions have leveled or even decreased slightly in the past several years, the use of platelets has continued to increase at a rate of at least 5 to 10 percent each year. This dramatic and continued increase in the use of platelet concentrates is largely the result of treating thrombocytopenic cancer patients. In addition, open heart surgery patients and others given massive transfusions also receive substantial platelet support. Nevertheless, it is the chronically transfused thrombocytopenic patient who frequently develops platelet alloimmunization and accounts for a large percentage of the increased demand for platelets. A recent survey in a large transfusion service indicated that 8 percent of the patients had received 35 percent of the random-donor pooled platelet concentrates. Although some alloimmunized patients can be supported by HLA-matched, apheresis-donor platelets, suitably matched donors are not available in sufficient numbers for every patient. Thus, platelet transfusion programs that could prevent, or at least delay platelet alloimmunization would be of substantial benefit. Limited studies have suggested several approaches that may reduce or prevent platelet alloimmunization: reducing the number of foreign antigens to which a recipient is exposed by providing single donor platelet apheresis products; providing leukocyte-poor blood products; inactivating donor antigen presenting cells (APC's), a type of lymphocyte contained within the transfused platelet products, by ultraviolet (UV) irradiation of platelet concentrates. The initiative was recommended by the Blood Diseases and Resources Advisory Committee in May 1987 and approved by the National Heart, Lung, and Blood Advisory Council in September 1987. The Requests for Applications were released in June 1988. DESIGN NARRATIVE: Randomized, double-blind. There were three treatment arms and one control arm. Patients in the treatment arms received either leukocyte-poor filtered pooled random donor platelets, or ultraviolet irradiated pooled random donor platelets, or leukocyte-poor filtered single donor apheresis platelets. Patients in the control group received routinely pooled, random-donor platelets. Patients remained on their assigned treatments for all transfusions through eight weeks. Assigned transfusions were discontinued only in the event of severe adverse reaction to the platelet transfusions, granulocyte transfusions, bone marrow transplant, withdrawal of informed consent, or death. Pre- and post transfusion counts were obtained for all platelet transfusions. Each patient was followed for one year. Recruitment continued through March 1995. Data analysis ended in July 1997.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind
Minimum Age/Maximum Age: 15 Years/75 Years
Genders: Both
Protocol Entry Criteria: Male and female thrombocytopenic patients, ages 15 and over, newly diagnosed with acute myelogenous leukemia (AML) and undergoing chemotherapy.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
HaydenBraine, , Johns Hopkins University
Additional Information:
Study ID Numbers: 309;
Study Start Date: August 1989
Record last reviewed: May 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000589
Other Hematologic Diseases Studies:
1. Prophylaxis Trial of Posaconazole vs. Standard Azole Therapy for Neutropenic Patients
2. Randomized double cord blood transplant study
3. Safety and Efficacy of Hum195/rGel in Patients with Advanced Myeloid Malignancies
4. Trial to Reduce Alloimmunization to Platelets (TRAP)
5. Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes
Related Studies:
Other Hematologic Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Trial to Reduce Alloimmunization to Platelets (TRAP)
|
|
|
|
|
|
|
|
